LENZ Therapeutics Inc
LENZ28.567USD
-1.393-4.65%
交易中 （美東）報價延遲15分鐘
814.16M總市值
虧損本益比TTM
關於 LENZ Therapeutics Inc 公司
LENZ Therapeutics, Inc. 是一家處於臨牀後期的生物製藥公司。該公司專注於開發首款基於乙酰克利定的眼藥水，以改善被診斷爲老花眼的患者的視力。其候選產品 LNZ100 和 LNZ101 是不含防腐劑的一次性眼藥水，每日使用一次，分別含有乙酰克利定和乙酰克利定加布林莫尼定。LNZ100 和 LNZ101 正在註冊授權 III 期 CLARITY 試驗中進行臨牀評估，作爲治療老花眼的潛在療法，老花眼影響着全球約 18 億人和美國 1.28 億人。
公司簡介
公司代碼LENZ
公司名稱LENZ Therapeutics Inc
上市日期Jun 25, 2021
CEOMr. Evert (Eef) Schimmelpennink
員工數量42
證券類型Ordinary Share
年結日Jun 25
公司地址- -
城市- -
上市交易所NASDAQ Global Select Consolidated
國家- -
郵編- -
電話- -
網址- -
公司代碼LENZ
上市日期Jun 25, 2021
CEOMr. Evert (Eef) Schimmelpennink
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Marc Odrich
Marc Odrich
Chief Medical Officer
Chief Medical Officer
99.60K
--
Shawn Olsson
Shawn Olsson
Chief Commercial Officer
Chief Commercial Officer
4.73K
+42.00%
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
3.19K
--
Dr. Zachary (Zach) Scheiner, Ph.D.
Dr. Zachary (Zach) Scheiner, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Ms. Shelley B. Thunen
Ms. Shelley B. Thunen
Independent Director
Independent Director
--
--
James Mccollum
James Mccollum
Independent Director
Independent Director
--
--
Dr. Frederic (Fred) Guerard, Pharm.D.
Dr. Frederic (Fred) Guerard, Pharm.D.
Independent Director
Independent Director
--
--
Jeff W. George
Jeff W. George
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Evert (Eef) Schimmelpennink
Mr. Evert (Eef) Schimmelpennink
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Marc Odrich
Marc Odrich
Chief Medical Officer
Chief Medical Officer
99.60K
--
Shawn Olsson
Shawn Olsson
Chief Commercial Officer
Chief Commercial Officer
4.73K
+42.00%
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
3.19K
--
Dr. Zachary (Zach) Scheiner, Ph.D.
Dr. Zachary (Zach) Scheiner, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Ms. Shelley B. Thunen
Ms. Shelley B. Thunen
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月16日 週五
更新時間: 5月16日 週五
持股股東
股東類型
持股股東
持股股東
佔比
RA Capital Management, LP
14.65%
Alpha Wave Global, LP
12.66%
Versant Ventures
12.15%
Ridgeback Capital Management, L.P.
6.84%
Point72 Asset Management, L.P.
6.60%
Other
47.09%
持股股東
持股股東
佔比
RA Capital Management, LP
14.65%
Alpha Wave Global, LP
12.66%
Versant Ventures
12.15%
Ridgeback Capital Management, L.P.
6.84%
Point72 Asset Management, L.P.
6.60%
Other
47.09%
股東類型
持股股東
佔比
Venture Capital
41.87%
Hedge Fund
24.75%
Investment Advisor
21.00%
Investment Advisor/Hedge Fund
11.47%
Individual Investor
2.76%
Research Firm
0.79%
Bank and Trust
0.13%
Pension Fund
0.05%
Insurance Company
0.02%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
244
29.26M
103.53%
-770.18K
2025Q1
245
28.95M
104.22%
-285.84K
2024Q4
225
27.65M
100.55%
-350.42K
2024Q3
204
26.43M
96.17%
-1.73M
2024Q2
197
25.06M
103.06%
+4.18M
2024Q1
204
22.41M
93.92%
+12.70M
2023Q4
200
7.73M
92.24%
-2.14M
2023Q3
200
7.54M
90.13%
-2.49M
2023Q2
212
7.64M
91.96%
-2.29M
2023Q1
205
7.41M
89.08%
-2.37M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
RA Capital Management, LP
4.18M
14.85%
--
--
May 07, 2025
Alpha Wave Global, LP
3.61M
12.83%
--
--
Apr 14, 2025
Versant Ventures
3.66M
12.99%
-884.80K
-19.48%
Jun 27, 2025
Ridgeback Capital Management, L.P.
1.95M
6.93%
--
--
Apr 14, 2025
Point72 Asset Management, L.P.
1.88M
6.69%
+1.03M
+120.91%
Apr 14, 2025
Paradigm BioCapital Advisors LP
1.42M
5.04%
-92.10K
-6.09%
Apr 14, 2025
The Vanguard Group, Inc.
1.20M
4.25%
+21.02K
+1.79%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.05M
3.73%
-14.66K
-1.38%
Mar 31, 2025
72 Investment Holdings, LLC
1.02M
3.62%
--
--
Mar 31, 2025
Sectoral Asset Management Inc.
977.25K
3.47%
--
--
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Harbor Health Care ETF
0.91%
Virtus LifeSci Biotech Clinical Trials ETF
0.89%
SPDR S&P Pharmaceuticals ETF
0.83%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.59%
iShares Micro-Cap ETF
0.12%
Invesco Nasdaq Biotechnology ETF
0.09%
ProShares Ultra Nasdaq Biotechnology
0.09%
iShares Biotechnology ETF
0.07%
Avantis US Small Cap Equity ETF
0.05%
Vanguard US Momentum Factor ETF
0.05%
查看更多
Harbor Health Care ETF
佔比0.91%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.89%
SPDR S&P Pharmaceuticals ETF
佔比0.83%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
佔比0.59%
iShares Micro-Cap ETF
佔比0.12%
Invesco Nasdaq Biotechnology ETF
佔比0.09%
ProShares Ultra Nasdaq Biotechnology
佔比0.09%
iShares Biotechnology ETF
佔比0.07%
Avantis US Small Cap Equity ETF
佔比0.05%
Vanguard US Momentum Factor ETF
佔比0.05%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Mar 19, 2024
Merger
7<1
Mar 19, 2024
Merger
7<1
Mar 19, 2024
Merger
7<1
Mar 19, 2024
Merger
7<1
公告日期
類型
比率
Mar 19, 2024
Merger
7<1
Mar 19, 2024
Merger
7<1
Mar 19, 2024
Merger
7<1
Mar 19, 2024
Merger
7<1
